Trial Profile
Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Inflammatory breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms NeoTRIPaPDL1; NeoTRIPaPDL1 Michelangelo
- 31 Jan 2024 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Results assessing efficacy of of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer presented at the 48th European Society for Medical Oncology Congress
- 14 Feb 2023 Planned End Date changed from 1 Oct 2022 to 1 Jan 2024.